国际眼科纵览

• 综述 • 上一篇    下一篇

角膜新生血管治疗的研究现状

温舒  杨炜   

  1. 832000 新疆,石河子大学医学院第一附属医院眼科(温舒系在读硕士研究生)
  • 收稿日期:2016-09-30 出版日期:2017-02-22 发布日期:2017-02-20
  • 通讯作者: 杨炜, Email: yangwei1959@126.com

The current research status of the corneal neovascularization treatment

WEN Shu, YANG Wei   

  1. Department of Ophthalmology, First Hospital Affiliated to Shihezi University, Shihezi Xinjiang Uygur Autonomous Region 832000, China
  • Received:2016-09-30 Online:2017-02-22 Published:2017-02-20
  • Contact: YANG Wei, Email: yangwei1959@126.com

摘要:

角膜新生血管是导致视力严重下降甚至致盲的重要病理性改变。随着细胞分子生物学、免疫学及药理学研究方法的进展,治疗角膜新生血管的方法不断取得突破。目前,临床常用的治疗方法包括糖皮质激素类药物、抗血管内皮生长因子、结膜移植、光动力疗法等。但尚无特效疗法。防治角膜新生血管发生是眼科领域研究的重点。(国际眼科纵览, 2017,  41:  43-47)

Abstract:

Corneal neovascularization(CNV) is one of the important pathological changes that leads to serious vision decline or even blindness. In recent years, with the deep study of molecular biology, immunology and pharmacology, the methods of treating CNV have made a breakthrough. At present, the common treatment methods include hormone drugs, anti-vascular endothelial growth factor, conjunctival transplantation, photodynamic therapy and so on. However, there is no effective therapeutic medicine or cure methods for CNV. How to prevent and treat CNV has become a hotspot in research in ophthalmology.  (Int Rev Ophthalmol,  2017,  41:   43-47)